nurixtx.comAbout company
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases. The company’s product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. The company discovers drugs that harness the body's natural process to control protein levels. Their focus is on developing drugs to treat cancer including the novel, small molecule immuno-oncology agents. Nurix was founded in 2009 by internationally recognized experts in the ubiquitin-proteasome field and is funded by leading life science investors, Third Rock Ventures, and The Column Group. The company is headquartered in San Francisco, California.
